Masimo v. Apple: Federal Circuit Dismissal in Sensor Patent Dispute
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Masimo Corp. gegen Apple, Inc. |
| Fallnummer | 24-1625 (Fed. Cir.) |
| Gericht | Federal Circuit, Appeal from PTAB (implied) |
| Dauer | Apr 1, 2024 – Jan 16, 2026 1 year 9 months |
| Ergebnis | Voluntary Dismissal – No Ruling on Merits |
| Streitige Patente | |
| Beschuldigte Produkte | Apple Watch models (optical sensing components) |
Fallübersicht
Die Parteien
⚖️ Kläger
Global leader in noninvasive patient monitoring technology, holding an extensive portfolio of patents related to pulse oximetry and wearable health sensors.
🛡️ Beklagter
Leading consumer electronics company whose Apple Watch series has become a central battleground for health monitoring patents, integrating blood oxygen and optical sensor technologies.
Streitige Patente
At the center of this proceeding was **U.S. Patent No. 7,761,127 B2** (Application No. 11/366,209), directed to a **multiple wavelength sensor substrate**. This patent covers a foundational architecture used in optical sensors that measure biological data — such as blood oxygen saturation — across multiple light wavelengths. This technology is critical to wearable health monitors, including smartwatches.
- • US 7,761,127 B2 — Multiple wavelength sensor substrate
Developing optical health sensors?
Check if your sensor design might infringe this or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
The Federal Circuit dismissed the proceeding pursuant to Fed. R. App. P. 42(b) — a voluntary dismissal by stipulation of the parties. The order specified that each side shall bear its own costs, a standard condition in stipulated dismissals that signals a negotiated resolution rather than a clear-cut winner or loser. No damages were awarded, and no injunctive relief was issued at this appellate stage.
Wichtige rechtliche Fragen
The **verdict cause is classified as “Patentability — Invalidity/Cancellation Action,”** indicating that Apple challenged the validity of U.S. Patent No. 7,761,127 B2, likely seeking cancellation of claims through a USPTO trial proceeding with subsequent appeal to the Federal Circuit. A Rule 42(b) dismissal at the appellate level typically reflects a **coordinated resolution across multiple fronts**, rather than an isolated appellate decision. The patent’s survival (or resolution by agreement) at the appellate stage means **U.S. Patent No. 7,761,127 B2 was not conclusively invalidated by this proceeding.** The claims covering the multiple wavelength sensor substrate remain part of Masimo’s enforceable portfolio unless addressed in other proceedings.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in wearable health sensor design. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- View 47 related patents in the optical sensor technology space
- See which companies are most active in health sensor patents
- Understand claim construction patterns for sensor substrates
🔍 Das Risiko meines Produkts überprüfen
Führen Sie eine umfassende FTO-Analyse für Ihre eigene Technologie oder Ihr eigenes Produkt durch.
- Geben Sie Ihre Produktbeschreibung oder technischen Merkmale ein.
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Hochrisikogebiet
Multiple wavelength sensor substrates
47 Verwandte Patente
In optical sensor design space
Design-Around-Optionen
Available for most sensor claims
✅ Wichtigste Erkenntnisse
Rule 42(b) stipulated dismissals at the Federal Circuit reflect strategic portfolio management, not litigation failure.
Verwandte Rechtsprechung suchen →Invalidity challenges to foundational platform patents carry high appellate costs with uncertain outcomes.
Präzedenzfälle erkunden →Häufig gestellte Fragen
The case involved U.S. Patent No. 7,761,127 B2 (Application No. 11/366,209), directed to a multiple wavelength sensor substrate — core technology in optical health monitoring devices.
The proceeding was dismissed pursuant to Fed. R. App. P. 42(b) by mutual agreement of the parties, with each side bearing its own costs. No judicial ruling on the merits was issued.
The patent survived the appellate proceeding without cancellation, reinforcing its enforceability. Companies developing optical biosensor products should conduct updated FTO analysis against Masimo’s portfolio.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- USPTO Patent Center — U.S. Patent No. 7,761,127 B2
- PACER Federal Court Records
- United States Court of Appeals for the Federal Circuit — Rule 42 Procedures
- U.S. Patent and Trademark Office — Patent Trial and Appeal Board (PTAB)
- PatSnap – Lösungen für den Umgang mit geistigem Eigentum für Anwaltskanzleien
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.